Current applications of monoclonal antibodies for the therapy of hematopoietic cancers

Curr Opin Immunol. 1991 Oct;3(5):679-84. doi: 10.1016/0952-7915(91)90096-j.

Abstract

Recent trials of monoclonal antibodies in patients with leukemias or lymphomas have demonstrated the remarkable potency of these agents to kill tumor cells specifically and safely. New molecular biological and radiochemical techniques are also allowing rapid inroads into the remaining obstacles to this mode of therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use
  • Hematopoietic Cell Growth Factors / antagonists & inhibitors
  • Hematopoietic Cell Growth Factors / immunology
  • Humans
  • Immunoglobulin Idiotypes / immunology
  • Immunotoxins / therapeutic use
  • Leukemia / immunology
  • Leukemia / radiotherapy
  • Leukemia / therapy*
  • Lymphoma / immunology
  • Lymphoma / radiotherapy
  • Lymphoma / therapy*
  • Mice
  • Protein Engineering
  • Radioimmunotherapy
  • Receptors, Cell Surface / antagonists & inhibitors
  • Receptors, Cell Surface / immunology
  • Vaccines

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Hematopoietic Cell Growth Factors
  • Immunoglobulin Idiotypes
  • Immunotoxins
  • Receptors, Cell Surface
  • Vaccines